Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFatigue is one of the recognised side effects of Mounjaro (tirzepatide), and it is common enough that many people starting treatment notice it within the first few weeks. It tends to appear after an injection, after a dose increase, or during the early weeks on a new strength — and for most people it eases as the body adjusts. Understanding why tiredness happens, what makes it worse, and when it is a signal to speak to your prescriber is the key decision this page helps you make. These are prescription-only medicines, and any changes to your treatment should involve a clinician who knows your full picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) that regulate appetite and slow the rate at which the stomach empties. That slowing is useful for reducing hunger, but it places real demands on the body's digestive processes. In the days after an injection, the system is doing more work, and that has an energy cost. Fatigue sits alongside nausea, constipation, and indigestion as part of the same GI adjustment picture, according to the NHS tirzepatide information page.
There is also a calories-in angle. When appetite suppression kicks in strongly (particularly in the first few weeks) some people eat far less than they realise. A meaningful calorie deficit, run hard, is physically tiring. That is not a reason to abandon the medicine; it is a reason to be intentional about what you eat, particularly protein, even when hunger is low.
Dehydration is underappreciated here too. If you are experiencing any nausea or loose stools (common in the early weeks), fluid losses can accumulate quietly. Even mild dehydration causes the kind of low-level fatigue that feels like it is coming from nowhere. A glass of water is not a treatment for a side effect, but it is a reasonable first check.
The decision most people face is not whether to stop Mounjaro but how to manage through the adjustment period. A few factors reliably worsen fatigue on tirzepatide, and each is worth working through before drawing conclusions about the medicine itself.
Sleep quality often dips in the early weeks if nausea is present at night. Some people also find they wake after injecting with a dull, heavy feeling the next morning. Timing the injection for a day when you can rest slightly more (some people choose a Friday evening) does not change what the medicine does, but it can reduce the impact on work and daily function. This is worth discussing with your prescriber rather than adjusting independently.
Physical activity is another factor. It sounds counterintuitive, but very light movement (a 15-minute walk) tends to reduce GLP-1-related fatigue more than rest alone. Sitting still with low energy can become its own feedback loop. On the other hand, heavy training sessions while eating significantly less than usual will deepen tiredness. Calibrating activity to your current intake is a conversation worth having with whoever is reviewing your progress; NHS England's guidance on weight-management injections highlights the importance of lifestyle support running alongside treatment for exactly this reason.
If you are wondering whether the cost of private treatment factors into whether to continue, the treatment options page sets out what is included at each stage, which is useful context before making any decisions.
Most fatigue on tirzepatide is self-limiting. It peaks in the first one to two weeks after starting or increasing a dose, then settles. That pattern is the reassuring one. The pattern that warrants a call to your prescriber (or, in some cases, urgent medical help) looks different.
Fatigue that is worsening rather than improving after two weeks on a stable dose, tiredness severe enough to affect daily functioning, or exhaustion that appears alongside new symptoms (significant heart palpitations, breathlessness, or severe abdominal pain that spreads to the back) should not be waited out. The MHRA issued specific guidance in January 2026 on acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, severe, persistent stomach pain reaching the back is the key symptom to know. Any version of that needs same-day medical attention, not an internet search.
Low mood or a sense of flatness is also worth naming. Fatigue and mood can be hard to separate, and some people find the early weeks on treatment emotionally as well as physically demanding. If that resonates, the page on Mounjaro and mood covers what the evidence says. Our full Mounjaro side effects guide is also useful alongside this one, and if nausea is part of what you are dealing with, the dedicated pages on Mounjaro making you feel sick and tirzepatide making you feel sick go into more detail on managing that specific side effect.
Suspected side effects can be reported directly to the MHRA using the Yellow Card scheme, patients can do this themselves, and it contributes to ongoing monitoring of tirzepatide in real-world use.
Tiredness that is disrupting daily life is worth raising, not pushing through silently. A prescriber can look at the full picture: what dose you are on, how long you have been at that level, what your diet and hydration look like, and whether a temporary pause in titration (staying longer on the current dose before moving up) might make the adjustment more manageable. That is a clinical decision, not one to make alone.
At nume, every prescription is reviewed by a GPhC-registered Independent Prescriber (a real clinician reading your notes) and aftercare support is available seven days a week. When your treatment arrives (a plain, unbranded box via DPD, trackable on your phone), the conversation with your prescriber does not end there. If you want to understand more about why Mounjaro makes you tired and what you can do about it in practical terms, our dedicated page covers the topic in full. You can also read more about how Mounjaro works and what the full treatment journey typically looks like.
If you are still deciding whether tirzepatide is the right route for you, exploring your treatment options is a sensible next step. When you are ready to speak to someone clinical, you can start a free consultation with our prescribers, no referral or waiting list involved.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.